The New York Times reports that the FDA has delayed its much anticipated ruling on generics until sometime in 2017. 

Morais and colleagues have published an informative review of rheumatologic and musculoskeletal (MSK) disorders that may potentially befall those with benign or malignant blood disorders. It is important to be aware of these associations.

Two recent surveys show that gout patients are often uninformed, undertreated, improperly monitored and frequently stigmatized by their gout.

Mechanisms underlying the pulmonary fibrosis of systemic sclerosis are poorly understood, yet are the focus of both research and new drug development. 

How would you manage rheumatoid arthritis patients with melanoma in situ, or high liver enzymes or interstitial lung disease? Curbside consults takes on these challenging therapeutic or safety issues with answers are based on experience, literature and guidelines.

Khanna and coworkers have published the results of the DUAL-1 and DUAL-2 clinical trials (sponsored by Actelion Pharmaceuticals) testing the efficacy macitentan in reducing the number of new digital ulcers in patients with systemic sclerosis.

Research presented at the annual British Society for Rheumatology conference revealed that rheumatoid arthritis patients who drink moderately while taking methotrexate appear to be at no greater risk for liver damage than nondrinkers.

Glucocorticoid (or steroid) therapy is a well-known risk factor for diabetes. But what dose, given how and for how long?  Dixon and colleagues from the The University of Manchester have quantified the risk of diabetes associated with steroid use.

An advisory panel to the Food and Drug Administration met May 3rd and 4th to review whether the long-acting or extended release (ER/LA) opioid REMS programs approved in 2012 have had a meaningful effect on the opioid abuse problems noted nationwide. The FDA panel voted overwhelming

Obesity is epidemic in North America, affecting nearly 76 million adults. Obesity is not only a risk factor for rheumatoid arthritis and osteoarthritis, it clearly worsens pain and function in most musculoskeletal (MSK) conditions and has been shown to blunt DMARD and biologic resp

Early referral and diagnosis remains a challenge for many who care for patients with musculoskeletal complaints.  This is especially so in those with chronic low back pain (LBP) and the minority who will have ankylosing spondylitis or axial spondyloarthritis.

Silverman and a panel from the IOF Fracture Working Group reviewed the data and trials to develop guidelines for the use of osteoporosis medications after incident fractures or to treat delayed fracture healing.

Doshi and colleagues have conducted a retrospective claims analysis (2009 through 2012) of psoriasis patients on Medicare to examine the use and adherence to those initiating treatment with either infliximab, etanercept, adalimumab, or ustekinumab.

Like other extraarticular manifestations, rheumatoid (RA) or connective tissue disease (CTD) related interstitial lung disease (ILD) is difficult to identify early and equally challenging to treat.

It is important to know where you’ve been, as it will most certainly color where you are going. Hence, in honor of our 1st year anniversary, we have taken note of our most popular articles.

Amidst a stringent regulatory environment, and with the rising use and abuse of narcotics and increasing regulation limiting narcotic analgesic use, the FDA approved (August 2015) the use of extended-release oxycodone in children (11 to 16 years old) with severe, "around-the-clock" pain

Harvey and coworkers reported the results of subjects followed in the Reykjavik study, demonstrating that a first osteoporotic fracture was followed by an increased risk for a second fracture, both immediately and over time.

Choi and colleagues analyzed US hospitalizations (2009–2013) to assess the frequency and racial distribution of patients hospitalized with Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) related to the use of urate-lowering (ULT) therapy (predominantly allopurinol).

In March 2016, RheumNow published 82 social media “tweets” regarding news, research and teaching points that impact the rheumatology community. These feeds had a reach (impressions) of 86,400 with, 76 mentions, and over 2700 visits to learn on RheumNow.com.

Dr. Jack Cush reviews the rheumatology highlights from the news, media, and journals from this past week: